Cooperative Human Tissue Network

Last updated

The Cooperative Human Tissue Network (the CHTN) was established in 1987 by the National Cancer Institute in response to an increase in the demand for high quality biospecimens for cancer research. The purpose of the CHTN is to stimulate, for the good of the public, cooperative efforts to collect and distribute human biospecimens and to thereby facilitate research utilizing those specimens. These activities are expected to encourage basic and developmental studies in many areas of cancer research, including molecular biology, immunology and genetics. The CHTN is not intended to be a human tissue bank, but instead procures tissue at the request of an investigator. Limited banking was to be done as needed to meet specific requests and longer-term banking of targeted specimens to assure availability of rare and hard to obtain materials. [1] It is funded under a UM1 NIH grant.

Contents

Divisions

The CHTN has six divisions, five adult divisions and one pediatric division. These divisions are located at the following institutions:

History

The CHTN was established in 1987 as the Cooperative Human Tissue Network by the National Cancer Institute's Cancer Diagnosis Program. [2] The University of Alabama at Birmingham, National Disease Research Interchange in conjunction with the hospital of the University of Pennsylvania, and The Ohio State University with a subcontract to Nationwide Children's Hospital were awarded the first Cooperative Human Tissue Network grant by the NCI. A second grant was funded during 1991-1995, and Case Western Reserve University (CWRU) joined the CHTN and Nationwide Children’s Hospital became an independent group. A third round of funding provided for 1996-2001, and the funding was transferred from NDRI to the University of Pennsylvania. The grant was renewed a fourth time for 2001-2006, in which the University of Virginia was added and Vanderbilt University Medical Center replaced Case Western Reserve University. A fifth grant was given for 2008 through 2013, and the sixth for 2014-2019, with supplemental funding bridging the years in between grants. The grant was renewed a seventh time for 2019-2024, in which Duke University replaced The University of Alabama Birmingham. [3] The name was changed in 2014 to the Collaborative Human Tissue Network. [4]

CHTN biospecimens

The CHTN obtains biospecimens from routine diagnostic or therapeutic surgical resections and autopsies, which otherwise would be discarded. Malignant, benign, diseased, and normal biospecimens are collected and distributed to both national and international investigators. In addition, remnant body fluids are available on some patients and limited histological services can be obtained by special arrangement. Requests for large sample sizes, large numbers of biospecimens, rare biospecimens, or biospecimens in high demand may be served if they do not negatively impact the availability of biospecimens for other researchers.

Investigators must complete a standard CHTN application which includes a brief description of their research project, funding information, and biospecimen requirements. In addition, researchers must submit documentation of his/her Institutional Review Board (IRB) approval or exemption.

The intent of the CHTN is to encourage research using human biospecimens for the good of the public rather than for private gain. The CHTN Agreement for Use of Tissue, which must be signed by all CHTN investigators, states “The recipient agrees that it shall not sell any portion of the tissues provided by the CHTN, or products directly extracted from these tissues (e.g. protein, mRNA or DNA). The recipient agrees that it shall not transfer tissue (or any portion thereof) supplied by the CHTN to third parties without the prior written permission of the CHTN.”

Policies and procedures for the protection of human subjects

The CHTN has established operating policies and procedures that protect the subjects from whom CHTN biospecimens are obtained. These policies and procedures are consistent with current regulations and guidance for repositories from the Office of Human Research Protections (OHRP) in the Department of Human and Health Services (DHHS). The following policies and procedures govern the collection of biospecimens and their distribution to researchers:

See also

Related Research Articles

<span class="mw-page-title-main">National Institutes of Health</span> US government medical research agency

The National Institutes of Health, commonly referred to as NIH, is the primary agency of the United States government responsible for biomedical and public health research. It was founded in the late 1880s and is now part of the United States Department of Health and Human Services. Many NIH facilities are located in Bethesda, Maryland, and other nearby suburbs of the Washington metropolitan area, with other primary facilities in the Research Triangle Park in North Carolina and smaller satellite facilities located around the United States. The NIH conducts its own scientific research through the NIH Intramural Research Program (IRP) and provides major biomedical research funding to non-NIH research facilities through its Extramural Research Program.

<span class="mw-page-title-main">Informed consent</span> Need and process for obtaining subject approval prior to treatment or research

Informed consent is a principle in medical ethics, medical law and media studies, that a patient must have sufficient information and understanding before making decisions about their medical care. Pertinent information may include risks and benefits of treatments, alternative treatments, the patient's role in treatment, and their right to refuse treatment. In most systems, healthcare providers have a legal and ethical responsibility to ensure that a patient's consent is informed. This principle applies more broadly than healthcare intervention, for example to conduct research and to disclose a person's medical information.

<span class="mw-page-title-main">Clinical trial</span> Phase of clinical research in medicine

Clinical trials are prospective biomedical or behavioral research studies on human participants designed to answer specific questions about biomedical or behavioral interventions, including new treatments and known interventions that warrant further study and comparison. Clinical trials generate data on dosage, safety and efficacy. They are conducted only after they have received health authority/ethics committee approval in the country where approval of the therapy is sought. These authorities are responsible for vetting the risk/benefit ratio of the trial—their approval does not mean the therapy is 'safe' or effective, only that the trial may be conducted.

<span class="mw-page-title-main">Human subject research</span> Systematic, scientific investigation that involves human beings as research subjects

Human subject research is systematic, scientific investigation that can be either interventional or observational and involves human beings as research subjects, commonly known as test subjects. Human subject research can be either medical (clinical) research or non-medical research. Systematic investigation incorporates both the collection and analysis of data in order to answer a specific question. Medical human subject research often involves analysis of biological specimens, epidemiological and behavioral studies and medical chart review studies. On the other hand, human subject research in the social sciences often involves surveys which consist of questions to a particular group of people. Survey methodology includes questionnaires, interviews, and focus groups.

The National Cancer Institute (NCI) coordinates the United States National Cancer Program and is part of the National Institutes of Health (NIH), which is one of eleven agencies that are part of the U.S. Department of Health and Human Services. The NCI conducts and supports research, training, health information dissemination, and other activities related to the causes, prevention, diagnosis, and treatment of cancer; the supportive care of cancer patients and their families; and cancer survivorship.

<span class="mw-page-title-main">Investigational New Drug</span> USFDA program and prodecures

The United States Food and Drug Administration's Investigational New Drug (IND) program is the means by which a pharmaceutical company obtains permission to start human clinical trials and to ship an experimental drug across state lines before a marketing application for the drug has been approved. Regulations are primarily at 21 CFR 312. Similar procedures are followed in the European Union, Japan, and Canada.

An institutional review board (IRB), also known as an independent ethics committee (IEC), ethical review board (ERB), or research ethics board (REB), is a committee at an institution that applies research ethics by reviewing the methods proposed for research involving human subjects, to ensure that the projects are ethical. The main goal of IRB reviews is to ensure that study participants are not harmed. Such boards are formally designated to approve, monitor, and review biomedical and behavioral research involving humans, and they are legally required in some countries under certain specified circumstances. Most countries use some form of IRB to safeguard ethical conduct of research so that it complies with national and international norms, regulations or codes.

The Belmont Report is a 1978 report created by the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. Its full title is the Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research, Report of the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research.

The Clinical Laboratory Improvement Amendments (CLIA) of 1988 are United States federal regulatory standards that apply to all clinical laboratory testing performed on humans in the United States, except clinical trials and basic research.

<span class="mw-page-title-main">Biobank</span> Repository of biological samples used for research

A biobank is a type of biorepository that stores biological samples for use in research. Biobanks have become an important resource in medical research, supporting many types of contemporary research like genomics and personalized medicine.

A Clinical Research Coordinator (CRC) is a person responsible for conducting clinical trials using good clinical practice (GCP) under the auspices of a Principal Investigator (PI).

<span class="mw-page-title-main">Public Responsibility in Medicine and Research</span> Nonprofit organisation

Public Responsibility in Medicine and Research (PRIM&R) is a 501(c)(3) nonprofit organization based in Boston, Massachusetts. The organization was formed in 1974 by a group of researchers who sought to ensure that the concerns and experiences of those working in biomedical research would be reflected in the growing body of federal regulations governing the field.

The Office for Human Research Protections (OHRP) is a small office within the United States Department of Health and Human Services (DHHS), specifically the Office of the Assistant Secretary for Health in the Office of the Secretary of DHHS, that deals with ethical oversights in clinical research conducted by the department, mostly through the National Institutes of Health (NIH).

A glossary of terms used in clinical research.

A tumor bank is sometimes also referred to as a Tissue Bank, since normal tissues for research are also often collected. However, this function is distinct from a Tissue Bank which collects and harvests human cadaver tissue for medical research and education, and banks which store Biomedical tissue for organ transplantation.

The Cancer Trials Support Unit(CTSU) is a service of the National Cancer Institute (NCI) in the United States.

<span class="mw-page-title-main">Biological specimen</span> Laboratory specimen used in biological research

A biological specimen is a biological laboratory specimen held by a biorepository for research. Such a specimen would be taken by sampling so as to be representative of any other specimen taken from the source of the specimen. When biological specimens are stored, ideally they remain equivalent to freshly-collected specimens for the purposes of research.

Various organizations have created guidelines for human subject research for various kinds of research involving human subjects and for various situations.

<span class="mw-page-title-main">Suzanne Rivera</span> American bioethicist and science policy researcher

Suzanne M. Rivera is an American bioethicist who is the president of Macalester College. She is the first female and first Latina president in the college's history. Rivera's presidential Inauguration ceremony was held at Macalester on October 9, 2021. Minnesota Gov. Tim Walz proclaimed it as "Suzanne M. Rivera Day" in the state.

Irina A. Lubensky is an American surgical pathologist serving as chief of the pathology investigation and resources branch at the National Cancer Institute.

References

  1. "Fueling Basic Discovery: NCI's Cooperative Human Tissue Network". National Cancer Institute. 7 March 2016. Retrieved 23 June 2019.
  2. "About CHTN". Cooperative Human Tissue Network (CHTN). Retrieved 23 June 2019.
  3. "CHTN's History". Cooperative Human Tissue Network (CHTN). Retrieved 23 June 2019.
  4. "RFA-CA-13-007: Collaborative Human Tissue Network (CHTN) (UM1)". Grants.nih.gov. Retrieved 23 June 2019.